Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is partnering with the American Cancer Society to spread awareness and encourage more at-risk South Texans to screen for lung cancer.
Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment. The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of […]
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (Nov. 1, 2022) – Lung cancer is the leading cause of cancer death in the United States, accounting for almost 25% of […]
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (mTNBC) who have not received previous therapy for advanced disease and whose tumors are PD-L1 positive (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score [CPS] ≥ 10) at screening.
This study evaluates the preliminary efficacy and safety of NIS793 and other novel investigational combinations with SOC anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of metastatic colorectal cancer.
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
Close
